PubMed Health⌕ Search

Biomedical subjects

N Niitsu

Publications and source records attributed to N Niitsu.

85 records · Page 5Linked to original sources
PubMed1993

[Elderly non-Hodgkin's lymphoma arising in left brachial soft tissue].

A 66-year-old woman visited a local hospital complaining of left brachial tumor in June 1988. She was diagnosed as having non-Hodgkin's lymphoma (diffuse medium-sized type) by biopsy of the tumor. No other lesions were detected at any site. The disease was classified as stage IA and radiotherapy was carried out resulting in complete remission (CR). Because a tumor was observed at the same site again she was admitted to our hospital. Under a diagnosis of recurrence, she received 2 courses of COP-BLAM therapy, and achieved CR. Subsequently she was treated with chemotherapy as an outpatient. As another tumor developed at the same site in June 1992, the patient was readmitted. The re-evaluation of clinical stage revealed no other lesions. Under a diagnosis of second recurrence, still in stage I, she underwent both chemotherapy (IMV-triple P therapy) and radiotherapy, and CR was achieved again. She is now being treated as an outpatient. Malignant lymphoma originating from soft tissue, particularly the skeletal muscle, is rare. The present case was considered to be rare because the tumor was a non-Hodgkin's lymphoma originating from the left brachial soft tissue, in which the tumor recurred twice at the same site.

Aged↗
PubMed1993

[COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].

Although the third generation regimens for the treatment of malignant lymphoma are used more predominantly than those of other generations in recent years, a number of elderly patients die due to the toxicity of those treatments. We treated elderly patients with non-Hodgkin's lymphoma (NHL) with COP-BLAM III, and compared its therapeutic and adverse effects on elderly NHL patients (more than 65 years of age) with those in non-elderly patients. Nine previously untreated elderly NHL patients (4 males and 5 females, with a median age of 71 years) and 13 previously untreated NHL non-elderly patients (6 males and 7 females, with a median age of 43 years) were treated with COP-BLAM III. According to the Ann Arbor staging rules for malignant lymphoma, 4 and 6 elderly patients were classified in stage III and IV, respectively, while 6 and 7 non-elderly patients were in stage III and IV, respectively. There were 5 elderly patients with diffuse large cell type lymphoma (D. large), 3 with diffuse medium-sized cell type (D. medium) and one with diffuse mixed-cell type (D. mixed), while there were 6 non-elderly patients with D. large, 6 with D. medium and one with D. mixed. The COP-BLAM III regimen consisting of portion A with continuous infusion of the drugs and portion B with intravenous bolus administration of drugs was identical to that used by Boyd et al. Portion A and portion B were repeated every 3 weeks alternatingly. The administration of granulocyte-colony stimulating factor (G-CSF) was started, when the granulocyte count fell to below 1,000/microliters.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

[A case of elderly Hashimoto disease presenting malignant lymphoma, gastric cancer and colon cancer].

An 87-year-old woman, who had been suffering from hypothyroidism and had been treated as an outpatient at our department since 1982, noticed left cervical swelling toward the end of November 1992. Because ultrasonic examination revealed a mass in her thyroid gland, she was admitted for a closer examination and additional treatment. Biopsy of thyroid gland revealed non-Hodgkin's lymphoma (NHL; the diffuse small cell type, B-cell origin). A part from the swelling of thyroid gland and the left cervical lymph node, performance of various examinations did not detected any other NHL lesions. Therefore, it was classified as stage II NHL according to the Ann Arbor classification. Laboratory data on admission were as follows; WBC 4,400/microliters, Hb 13.6 g/dl, platelet count 10.1 x 10(4)/microliters, GOT 51 IU/l, GPT 31 IU/l, TSH 1.17, free-T4 1.03, free-T3 2.04, and microsome test 1,600 x. Those data indicated marked hypothyroidism. In addition, stage IIa and IIc gastric cancers were detected by the examination with gastric endoscopy performed for stage classification. Both were adenocarcinomas. Because polyps were found in her sigmoid colon with colonoscopy, polypectomy was performed. The polyps were diagnose histologically as moderately differentiated adenocarcinoma. On July 20, COP-BLAM therapy was started (CPM 600 mg div, VCR 1.2 mg iv, ADR 30 mg iv on day 1, PDN 40 mg p.o and PCZ 100 mg p.o. on days 1-10, BLM 7.5 mg div on day 14). Subsequently, the left cervical lymph node swelling disappeared, and shrinkage of the mass in the thyroid gland was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenocarcinoma↗
PubMed1993

[Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].

ACVP-16 chemotherapy combined with recombinant granulocyte-colony stimulating factor (rG-CSF) was carried out on patients with malignant lymphoma which were recurrent or resistant to chemotherapy including adriamycin. Twenty patients with non-Hodgkin's lymphoma, 11 men and 9 women, with a median age of 54 years, were entered in this study. Fourteen patients had diffuse large cell lymphoma, 4 diffuse medium, and 2 diffuse mixed. The previous treatments for these patients were COP-BLAM, IMV-triple P and COP-BLAM III. The ACVP-16 regimen included ara-C at 100 mg/m2 i.v. on day 1 to 5, CBDCA at 250 mg/m2 i.v. on day 1, and VP-16 at 70 mg/m2 i.v. on day 1 to 3. Subcutaneous administration of rG-CSF at 2 micrograms/kg was started on day 7. Since complete remission was achieved in 7 patients (35%) and partial remission in 8 (40%), the total response rate was 75%. The median survival duration after the initiation of this therapy was 11 months for those who achieved CR and 4 months for those who achieved PR and those who had no response. Leukopenia (< or = 1,000/microliters) and thrombocytopenia (< or = 50,000/microliters) were observed in 15 (75%) and 12 (60%), respectively. We conclude that the ACVP-16 regimen is useful for the treatment of refractory or relapsed non-Hodgkin's lymphoma. However, the patients who are treated with this regimen should be carefully managed in order to avoid severe infection, because leukopenia was observed even when rG-CSF was administered.

Adult↗
PubMed1988

Upper GI examinations in older premature infants with persistent apnea: correlation with simultaneous cardiorespiratory monitoring.

Upper gastrointestinal examinations with simultaneous cardiorespiratory monitoring were performed in 39 older premature infants with persistent apnea. Swallowing incoordination was documented to be causatively related to persistent apnea in such infants, especially with feeding. Direct relationship between apnea and gastroesophageal reflux was not documented in this study.

Apnea↗
PubMed1977

Neonatal hypophosphatasia with elevated serum parathyroid hormone.

Two cases of neonatal hypophosphatasia are described. In case 1, hypercalcemia developed at 2 1/2 months of age and continued until death at 10 1/2 months of age. Serum calcium levels decreased transiently in response to phosphate supplementation, prednisolone, and calcitonin. Significantly elevated levels of PTH were detected at 2 1/2 months of age. At autopsy, no parathyroid glands were found. In case 2, hypercalcemia was not detected in his course. Elevated level of serum PTH was recorded on the 17th day of life. A post-mortem examination revealed the presence of one normal parathyroid gland.

Autopsy↗
PubMedDate not supplied

Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor.

Serum (beta 1-->3)-D-glucan was elevated in 34 of 126 patients (27%) with hematologic malignancy who were clinically suspected of having a deep-seated mycosis. Although 11 patients (8.8%) were thought to have fungemia, fungi were isolated from blood culture in only 4. These results suggest that measurement of serum beta-D-glucan is useful for early diagnosis. Therapy with fluconazole (FLCZ) was effective in 9 of 11 patients (81.8%) suspected of having fungemia. Fungemia responded in 5 of 7 patients who were given granulocyte-colony-stimulating factor (G-CSF) concomitantly with FLCZ. This result suggested that administration of G-CSF with FLCZ was useful therapy for fungemia, which may occur during granulocytopenia following chemotherapy with anticancer agents.

Adjuvants, Immunologic↗
PubMedDate not supplied

[Clinical analysis of elderly patients with malignant lymphoma].

An epidemiological study on 173 consecutive elderly malignant lymphoma patients age 65 years or over was performed and the clinical outcome of chemotherapy is reported. Of there, 131 patients (75.7%) had non-Hodgkin's lymphoma (NHL) and 21 patients had Hodgkin's disease (HD). As for clinical staging, 58.9% of patients were in stage 3 or 4. The initial sites were nodal in 61.8% of the patients the most common sites of involvement in superficial lymph nodes being cervical, inguinal and axillar. The most frequent site of extranodal involvement was the gastrointestinal tract. The cases were treated with CHOP/COPP, BACOP or COP-BLAM combination chemotherapy. The clinical efficacy of these modalities was similar, with complete remission rates being about 50%. However, the total response rate (CR+partial remission) by the COP-BLAM regimen were 88.1%. The median survival time of cases achieving CR, was longer than 47 months. The most frequent cause of death was infection, especially pneumonia and septicemia. Many elderly ML patients were found and diagnosed when the disease developed to an advanced stage. Therefore it is necessary to make efforts to find early ML patients by screening apparently healthy elderly people. Improvement of the complete remission rate should be obtained if vigorous and intensive chemotherapy is carried out with careful supportive therapy concerning the general condition and complications in patients.

Age Factors↗
PubMedDate not supplied

Cardiotoxicity of combined administration of adriamycin and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats-with special reference to 125I-MIBG cardioautoradiography and histopathological findings.

We studied whether adriamycin(ADM)-induced myocardial disorder in rats is advanced when recombinant human granulocyte colony-stimulating factor (rhG-CSF) is administered. Rats were divided into three groups (15 rats/group), i.e. the ADM group, the ADM+rhG-CSF group, and the vehicle-treated control group. ADM (2 mg/kg, i.p.) was administered for the first 2 days in each cycle and 10 days of administration of rhG-CSF (50 micrograms/kg, s.c.) was started two days after the second dose of ADM was given in each cycle. The dosing cycle was repeated 3 times. One day after the last dose, the following parameters were analyzed: peripheral blood and bone marrow cells, electrocardiogram (ECG) and histopathological findings. Four hours after intravenous administration of 125I-metaiodobenzylguanidine (125I-MIBG), accumulation of 125I-MIBG in some organs and findings from autoradiography (ARG) of the heart were examined. ECG revealed an extended ventricular activation (VAT) time in the ADM and ADM+rhG-CSF groups. In histopathological analysis, vacuolar degeneration of the myocardium was observed in both the ADM and ADM+rhG-CSF groups. The degree of change was the same for both groups. The accumulation of 125I-MIBG in the heart was lower in both the ADM and ADM+rhG-CSF groups than in the control group. The same tendency was observed in ARG, but the difference between the ADM group and the ADM+rhG-CSF group was not significant. These results suggest that administration of rhG-CSF at the standard clinical dose does not aggravate ADM-induced myocardial disorder. However, because this disorder may be more clearly manifested by treatment with higher doses of ADM, it is necessary to conduct further studies on the methods of dosing and administration.

Animals↗